When IBSA Farmaceutici introduced Profhilo to the UK market, it did not simply add another product to the skin booster category — it created an entirely new one. Bio-remodelling is now one of the most important concepts in modern aesthetic medicine, and understanding why requires a close look at the science that underpins it.
What Makes Profhilo Different
Traditional dermal fillers use cross-linked hyaluronic acid (HA) to add volume. Classic skin boosters — micro-injected dilute HA — hydrate the dermis but offer limited structural benefit. Profhilo sits in neither category. It uses IBSA's patented NAHYCO technology, which combines high-molecular-weight HA (H-HA) and low-molecular-weight HA (L-HA) in a thermal cross-linking process that requires no chemical agents. The result is a uniquely stable, highly concentrated 64mg/2ml formulation that behaves unlike anything else available.
The absence of chemical cross-linking agents — typically BDDE, used in conventional fillers — is clinically significant. BDDE-free formulations carry a different safety profile, and the thermal hybrid complex creates a product with exceptional resistance to the enzyme hyaluronidase, giving it a longer bioresidence time than either H-HA or L-HA alone.
How the Science Translates to Results
When injected, Profhilo spreads across a wide tissue plane rather than staying localised. This hydrolift effect improves tissue hydration across the entire treated area simultaneously. More importantly, clinical studies have demonstrated that NAHYCO technology significantly increases elastin expression in dermal fibroblasts — stimulating tissue regeneration, not just surface hydration. Independent research has shown Profhilo to outperform both H-HA and L-HA applied separately in terms of elastin stimulation and resistance to enzymatic degradation.
The standard protocol uses the BAP (Bio Aesthetic Points) technique — five precise injection points per side of the face, placed anatomically to maximise product diffusion across the cheek, perioral and neck areas while minimising risk to vascular structures. Two sessions spaced four weeks apart form the recommended starter course, with a maintenance treatment at six months.
Why the UK Market Responded So Strongly
The UK aesthetics market had been waiting for a treatment that addressed the skin quality concerns of patients who did not want — or were not suitable for — volume-adding filler. Profhilo filled that gap precisely. Patients in their late thirties and forties, noticing a loss of firmness and radiance rather than volume, found a treatment that met their needs without the risks associated with large-volume injection. The treatment is also highly suitable for the neck and décolletage — areas historically underserved by injectable aesthetics.
Since its arrival, Profhilo has won multiple industry awards including Product Innovation of the Year at the UK Aesthetics Awards and the International Anti-Aging and Beauty Trophy at the European Congress of Aesthetic Medicine. Its growth in the UK has been remarkable: by 2021 it had become one of the top five most requested injectable treatments nationwide.
Who Is It Suitable For?
Profhilo is appropriate for most adults experiencing loss of skin laxity, hydration or quality in the face, neck, décolletage or hands. It is not a replacement for volume-restoring filler in patients with significant tissue loss — a thorough consultation will always determine whether bio-remodelling, volumisation, or a combination approach is the right path. At Cosmetica, Tracy assesses every patient individually before recommending a course of treatment.